This is a piece of what we sent our Free members on Dec 17th at 43 cents per share. The stock is now 49 cents up about 14% or so.
Join us free at stockreversals.com for the best ideas and market face ripping gain potential.
ONCS- 110 million market cap, 44 cents, recently traded at 62 cents in early December on spate of positive data from trials, partnerships, and more.... has pulled back on likely year end tax and profit related selling. Non-invasive investigational therapies that are designed to destroy solid tumors and metastatic cancer and preserve quality of life.
The total market cap is 100 million compared to 2.5 billion for Bluebird for example. One of Merck's top scientists who has 50 published peer reviewed white papers left Merck last year to join ONCS as their Chief Medical Officer. We expect at some point they will do a reverse split to move the share price up and get institutions involved.
The CEO and Founder was a V.P. at INO (Inovio). In recent studies their T-Cel therapies showed complete immune response rates and partial response rates in over 30% of patients. The stock is flying under the radar and though it may take some time to get legs, we are picking up an initial small position and then watching the news closely.
We are borrowing this 1 Billion valuation analogy (A 10 bagger if so) by a poster who has done his homework. https://docs.google.com/document/d/1aaIQRFno3T5W7PDDsPffAt6v7-SjHUDBziUARVjuevw/edit
So although Biotech has been hot and could correct hard at anytime, we are living in a great period and T-Cell immunotherapy and CAR-T technologies may be transforming cancer treatment unlike anything we have seen in 20-30 years
Disclosure: The author is long ONCS.
Additional disclosure: high risk, we have only 2% of our portfolio in this position.